First patient outside U.S. treated in global Kevzara® (sarilumab) clinical trial program for patients with severe COVID-19
- Details
- Category: Sanofi
The first patient outside of the U.S. has been treated as part of a global clinical program evaluating Kevzara® (sarilumab) in patients hospitalized with severe COVID-19. The global clinical program has now been initiated in Italy, Spain, Germany, France, Canada, Russia and the United States - all countries that have been impacted by COVID-19.
Consignment of 30 million hydroxychloroquine tablets ships to US Department of Health and Human Services
- Details
- Category: Novartis
Novartis announced that Sandoz, its generics and biosimilars division, has started to ship a consignment of 30 million doses of hydroxychloroquine tablets to the US Department of Health and Human Services (HHS) for immediate use in controlled clinical studies. The study will evaluate the medicine's effectiveness in people who have tested positive for COVID-19.
Novartis and life sciences companies commit expertise and assets to the fight against COVID-19 pandemic alongside Bill & Melinda Gates Foundation
- Details
- Category: Novartis
Novartis and a consortium of life sciences companies announced an important collaboration to accelerate the development, manufacture and delivery of vaccines, diagnostics, and treatments for COVID-19 in response to the pandemic. The industry brings a range of assets, resources, and expertise needed to identify effective and scalable solutions to the pandemic that is affecting billions worldwide.
Amgen and the Amgen Foundation commit up to $12.5 million to support COVID-19 relief efforts
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) and the Amgen Foundation announced an initial commitment of up to $12.5 million to support U.S. and global relief efforts to address critical needs in communities impacted by the COVID-19 pandemic. The funds will be used to support emergency response efforts in Amgen's U.S. and international communities, patient-focused organizations that are mounting their own response efforts, and international relief efforts by Direct Relief and International Medical Corps.
Roche response to COVID-19 pandemic
- Details
- Category: Roche
Roche Group (SIX: RO, ROG; OTCQX: RHHBY), provided an update on the various actions the company is taking to address the COVID-19 pandemic.
On March 19, 2020, Roche confirmed initiation of a randomised, double-blind, placebo-controlled Phase III clinical trial in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), a part of the US Health and Human Services Office of the Assistant Secretary for Preparedness and Response (ASPR).
AstraZeneca to donate 9 million face masks to support healthcare workers around the world in the fight against COVID-19
- Details
- Category: AstraZeneca
AstraZeneca is donating nine million face masks to support healthcare workers around the world as they respond to the COVID-19 (novel coronavirus) global pandemic. AstraZeneca has partnered with the World Economic Forum's COVID Action Platform, created with the support of the World Health Organisation, to identify countries in greatest need.
Novartis commits to donate up to 130 million doses of hydroxychloroquine to support the global COVID-19 pandemic response
- Details
- Category: Novartis
Novartis announced its commitment to donate up to 130 million doses of generic hydroxychloroquine to support the global COVID-19 pandemic response. Hydroxychloroquine and a related drug, chloroquine, are currently under evaluation in clinical trials for the treatment of COVID-19.
More Pharma News ...
- Roche initiates Phase III clinical trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 pneumonia
- Free EDC software for non-profit COVID-19 related studies
- Novartis announces broad range of initiatives to respond to COVID-19 Pandemic; Creates USD 20 million global fund to support impacted communities
- Roche's cobas SARS-CoV-2 Test to detect novel coronavirus receives FDA Emergency Use Authorization
- U.S. Food and Drug Administration approves Opdivo® (nivolumab) + Yervoy® (ipilimumab) for patients with hepatocellular carcinoma (HCC) previously treated with sorafenib
- Voluntis and Bristol-Myers Squibb to co-develop digital therapeutics for oncology
- International research partnership and EDCTP to invest €44m in next-generation antimalarials to combat drug-resistant malaria in Africa